Dr. Esther Oliva: Azacitidine As Post-Remission Therapy in Elderly Patients with AML

ASH 2014 – Dr. Esther Oliva discusses interim results on a Phase III, prospective, randomized, open-label, multicenter trial is designed to assess the efficacy of post-remission treatment with 5-Aza versus best supportive care -BSC- in 54 patients older than 60 years of age with AML in CR after conventional induction 3+7 and consolidation chemotherapy.